---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034506"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:04:15.936865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M

## Summary
- Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.
- Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.
- Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.
- SG&A rose 10% to $44.4M due to Emrosi commercialization costs.
- Accutane revenue declined $6.5M amid competitive pressures.

## SEC filing metadata
- accession: 0001104659-26-034506
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/0001104659-26-034506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034506
- JSON: https://secwatch.observer/filing/0001104659-26-034506.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.